Ποια είναι η τιμή για Psyence Biomedical Ltd. (PBM)

Η τιμή για Psyence Biomedical Ltd. (PBM) είναι $3.20

Ποια είναι η κεφαλαιοποίηση αγοράς για Psyence Biomedical Ltd. (PBM)

Η κεφαλαιοποίηση αγοράς για Psyence Biomedical Ltd. (PBM) είναι $60.86K

Psyence Biomedical Ltd. (PBM) Τιμή και Κεφαλαιοποίηση Αγοράς

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Η τιμή για PBM	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$283,051,657 $60.86K	NVDA	$5.383T	+8,845,364,173.88%
$234,322,753 $60.86K	AAPL	$4.457T	+7,322,585,917.73%
$218,464,111 $60.86K	GOOG	$4.155T	+6,827,003,361.16%
$192,613,746 $60.86K	MSFT	$3.663T	+6,019,179,465.50%
$152,017,919 $60.86K	AMZN	$2.891T	+4,750,559,858.79%

Η τιμή για PBM

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$283,051,657 $60.86K